Au­ris tries to re­bound from PhI­II fail­ure with new tri­al de­sign; Kymab ties the knot with Shang­hai-based EpimAb

Two months af­ter its shares were crushed in a rout fol­low­ing the fail­ure of a key late-stage study of its tin­ni­tus treat­ment, Au­ris Med­ical $EARS is ask­ing to change up the on­go­ing Phase III fol­lowup tri­al in an at­tempt to sal­vage a vic­to­ry out of the ef­fort. Work­ing off the first round of da­ta, Au­ris wants to el­e­vate the change in Tin­ni­tus Func­tion­al In­dex (TFI) scores from a key sec­ondary end­point to an al­ter­nate pri­ma­ry ef­fi­ca­cy end­point. The biotech says it’s pre­pared to ex­pand the study to make the change work for reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER